WFH ... WTF ... ????: Working-from-home, employer reaction and pandemic-inspired industrial changes

Time to Build More Windmills: Reflections from the ChinaBio Innovation & Investment Conference 2023

Arm Doors and Cross-Check: What the Health Sector Can Learn from the Post-COVID Airline Industry

Workers of the world resign!: What if post-pandemic staff refuse to return to the office?

Opportunities for the Life Science Industry in Australia post-COVID

The new frontier: emerging regulatory issues in cell and gene therapies

Creeping Through the Backdoor: Disruption in Medicine and Health

When profit isn’t everything: 46,000 years of cultural history vs the iron ore spot price

Space X and NASA: lessons on public-private R&D for the health debate

New industrial policy for biopharmaceutical and devices industry needs careful thought

HTA 2.0: time for a reboot

Alzheimer's failure a lesson in why pharma companies are vital

Crouching dragons and hidden tigers: the emergence of China’s life sciences sector

My failure as a Rockstar: lessons from technological change in the music industry

Doing it for Jane: eradicating tuberculosis

To price or not to price, that is the question

Don't forget the future: Alzheimer's disease and the economics of drug development

Disruptive innovation in the health sector – are we ready for it?

Innovation policy is the new black

Memo to life sciences executives: Happy New Year, take a deep breath and think big